PD-L1 has been widely studied in various types of cancer, and multiple immunohistochemistry assays have been approved as complementary diagnostics for patients with non-small cell lung cancer (NSCLC), melanoma, urothelial bladder cancer, esophageal, and gastric cancer66,67. The gene discussed is CD274; the disease is melanoma.